Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.
Times cited: 160
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study.
Journal of Clinical Oncology.
Times cited: 67